• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Nonviral Liposomes

        互联网

        1140
        Cationic liposome/micelle-based systems have come closer to providing clinically effective gene delivery than any other chemical nonviral delivery systems to date. These systems are formed from either a single synthetic cationic amphiphile (known as a cytofectin; cyto for cell and fectin for transfection [i.e., gene delivery and expression]) or, more commonly, from the combination of a cytofectin and a neutral lipid such as dioleoyl l -α-phosphatidylethanolamine (DOPE) or cholesterol (Chol) (see Fig. 1 ). There are at least 40 cationic liposome/micelle systems that have been reported to mediate nucleic acid delivery to cells, of which a number have been commercialized (see Table 1 ) (1 25 ). More are being reported all the time, but in each case, the key ingredient is the cytofectin used. The structures of a number of representative diverse cytofectins are shown (see Fig. 1 ). Although hydrophobic regions are reasonably similar, polar linkers and cationic head groups vary quite substantially. Typically, cytofectin and neutral lipid components are mixed together in an appropriate mole ratio and then induced or formulated into unilammellar vesicles by any one of a number of methods, including reverse-phase evaporation (REV) and dehydration-rehydration (DRV) (1 ,2 ) (see Table 1 ). Alternatively, cytofectins may be assembled into micellar structures after being dispersed in water or aqueous organic solvents (1 ,2 ) (see Table 1 ). Unilammellar vesicles or micelles may then be combined with nucleic acids to form cationic liposome/micelle-nucleic acid complex (lipoplex; LD) mixtures consisting of nanometric complex structures that are able to deliver nucleic acids into cells (see Fig. 2 on p. 108–111).
        http://img.dxycdn.com/trademd/upload/asset/meeting/2014/02/13/B1392271707.jpg
        Fig. 1.  (A-D ) Summary of structures of the main cytofectins and neutral lipids as described in the text and in Table 1 , p.112.

        http://img.dxycdn.com/trademd/upload/asset/meeting/2014/02/13/B1392271706.jpg
        Fig. 2.  Diagram showing process of LD complex cell entry. LD particles that have not succumbed to aggregation and/or serum inactivation associate with the cell surface and enter usually by endocytosis. The majority in early endosomes become trapped in late endosomes (path A) and the nucleic acids fail to reach the cytosol. A minority are able to release their bound nucleic acids into the cytosol. Path B is followed by RNA that acts directly in the cytosol. Path C is followed by DNA that enters the nucleus in order to act. The diagram is drawn making the assumption that plasmid DNA has been delivered, which is expressed in an epichromosomal manner. Reproduced from ref. 26 with the permission of BIOS Scientific Publishers Ltd.

        Table 1  Roche Molecular Liposome/Micelle Systems

        Cytofectin

        Formulation

        Trade name/manufacturer

        Ref.

        Commercialized

        DOTMA

        DOTMA/DOPE 1:1 (w/w)

        Lipofectin TM/Gibco-BRL

        3

        DOTAP

        DOTAP

        DOTAP/Roche Molecular

        4

        DOSPA

        DOSPA/DOPE 3:1 (w/w)

        LipofectAMINE TM/Gibco-BRL

        5

        DMRIE

        DMRIE/Chol 1:1 (m/m)

        DMRIE-C/Gibco-BRL

        6

        Tfx

        Tfx/DOPE (Tfx-10, -20, -50)

        TfxTM/Promega

        7

        DOGS

        Micelle

        Transfectam�/Promega

        8

        DDAB

        DDAB/DOPE 1:2.5 (w/w)

        LipofectACETM/Gibco-BRL

        10

        DC-Chol

        DC-Chol/DOPE 6:4 (m/m)

        DC-Chol/Sigma

        11

        DOSPER

        DOSPER

        DOSPER/Roche Molecular

        12

        Not commercialized

        RPR 120535

        Micelle

         

        14

        Cholic acid hexamine

        Cholic acid hexamine/DOPE 1:1 (w/w)

         

        15

        GL-67

        GL-67/DOPE 1:2 (m/m)

         

        16

        CTAP

        CTAP/DOPE 1:2 (m/m), 6:4 (m/m)

         

        17

        BGTC

        BGTC/DOPE 3:2 (m/m)

         

        19

        DOTIM

        DOTIM/Chol 1:1 (m/m) or DOTIM/DOPE 1:1 (m/m)

         

        20

        SAINT

        SAINT/DOPE 1:1 (w/w)

         

        21

        DODAC

        DODAC/DOPE 1:1 (m/m)

         

        22

        Lipid-glycoside

        Lipid-glycoside

         

        23

        DC-6-14

        DC-6-14/DOPE/Chol 4:3:3 (m/m/m)

         

        24

        EG316

        EG316/Chol 1:1 (w/w)

         

        25

        Abbreviatio ns: w/w: weight ratio; m/m: mol ratio; DOPE, dioleoyl-scL-α-phosphatidylethanolamine; DOTMA, N -[1-(2,3-dioleyloxy)propyl]-N,N ,N-trimethyl ammonium chloride; DOTAP,1,2-dioleyloxy-3-(trimethylammonio)propane; DOSPA, 2,3-dioleyloxy-N -[2-(sperminecarboxamido)ethyl]-N ,N-dimethyl-lpropanaminium trifluoroacetate; DMRIE, 1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium bromide; DOGS, dioctadecylamidoglycylspermine; DDAB, dimethyldioctadecylammonium bromide;DC-Chol,3β-[N -(NN ′-dimethylaminoethane)carbamoyl]cholesterol; DOSPER, 1,3-dioleoyloxy-2-(6-carboxyspermyl)propylamide; CTAP, 15 -cholesteryloxycarbonyl-3,7,12-triazapentadecane-1,15-diamine; BGTC, bis-guanidinium-tren-cholesterol; DOTIM, 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium choloride; SAINT, synthetic amphiphiles interdisciplinary; DODAC, dioleyldimethylammonium chloride; DC-6-14, O ,O′-ditetradecanoyl-N (α-trimethylammonioacetyl)diethanolamine chloride; EG316, dioleyl 2-(trimethylphosphonio)ethylphosphonate iodide.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序